Bregantini D, Schmitt LHM, Thijssen JJJ. A Bayesian change-point detection approach to the economic evaluation of risky projects: an application to healthcare technology assessment. J R Stat Soc Ser A Stat Soc. 2024 Apr;187(2):474-6. doi: 10.1093/jrsssa/qnad129
Raccah D, Guerci B, Ajmera M, Davis K, Meyers J, Lew E, Shaunik A, Blonde L. Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: an electronic medical record database analysis. Endocrinol Diabetes Metab. 2019 Mar 28;2(3):e00061. doi: 10.1002/edm2.61
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Rothman KJ, Hatch EE, Poole C, Wise LA, Gallacher JEJ, Lash TL, Mikkelsen EM, Sorensen HT. Comment on "Perils and Potentials of Self-Selected Entry to Epidemiological Studies and Surveys". J R Stat Soc Ser A Stat Soc. 2016 Feb;179(2):364. doi: 10.1111/rssa.12136
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.